NOP53 and ovarian carcinoma: Interestingly, we have shown in our study that HMGB1, HMGB2 and their EOC-HMGB-interactome partners MIEN1 and NOP53 are involved in the response to carboplatin, or drugs nowadays used in ovarian cancer treatment, such as bevacizumab, olaparib and paclitaxel.